ClinicalTrials.gg
RecruitingNCT07655375MASTGUTUpdated Sep 10, 2026

Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut

An interventional study of Sample collection in IBS (Irritable Bowel Syndrome), sponsored by Guy Boeckxstaens. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Guy Boeckxstaens · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Irritable Bowel Syndrome with a site in Belgium — 12 open to participants now, 13 under way, 3 of them phase 3. Irritable Bowel Syndrome · Belgium.

Planned enrollment
20th of 29
60 · median 90
Started
2026
with 3 others
No phase
16 of 32
7 open now
Primary completion
2027-10
later than 7 of 12 live
Registered
32nd of 32
by date
Lead sponsor
2 of 32
Guy Boeckxstaens

Among the 32 studies in Irritable Bowel Syndrome with a site in Belgium, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 32nd registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

12 of the 32 studies in Irritable Bowel Syndrome with a site in Belgium are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Irritable Bowel Syndrome with a site in Belgium, or all of them as a file.
02

Study summary

Study evaluating the effect of UCB8600 on mast cell activation in the human gut:

IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success.

Recently, we were able to demonstrate that mast cells play an active role in IBS symptoms. More specifically, they set histamine free when activated which heightens nerve sensitivity in the intestines which probably contributes to the abdominal pain. A new product called "UCB8600" is hypothesized to be able to counteract this by causing less mast cells to be activated. In this study we'll test this by administering UCB8600 on intestinal tissue and see if there is less mast cell activation. If the study produces good results, this new product could potentially be used as a treatment for IBS in the future.

03

Conditions studied

  • IBS (Irritable Bowel Syndrome)

Keywords

  • IBS
  • irritable bowel syndrome
  • UCB8600
  • mast cells
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):

  1. Voluntary written of the participant has been obtained prior to any screening procedures
  2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
  3. Undergoing surgery for colorectal cancer
  4. No preoperative radiotherapy or chemotherapy

Exclusion Criteria group 1 (resection tissue from surgery patients = healthy volunteers):

  1. Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhautive list) at the moment of surgery
  2. Inflammatory bowel disease (IBD) or diverticulitis
  3. Diabetes or ≥ 30 kg/m²
  4. Subject is legally incapacitated

Inclusion Criteria group 2 (rectal from IBS patients):

  1. Voluntary written informed consent of the subject has been obtained prior to any screening procedures
  2. At least 18 years of age and maximum age of 65 years of age at the time of signing the Informed Consent Form (ICF)
  3. Diagnosed with IBS

Exclusion Criteria group 2 (rectal biopsies from IBS patients):

  1. Subject has internal/external hemorrhoids at the moment of biopsy sampling.
  2. Using bloodthinners such as Acenocoumarol, Aspirine (acetylsalicylzuur), Apixaban (Eliquis), Clopidogrel (Plavix), Dabigatran (Pradaxa), Edoxaban (Lixiana), Rivaroxaban (Xarelto), warfarine (Marevan®) and Enoxaparine (Clexane), … (non-exhausative list).
  3. Using antihistamines such as ebastine, cetirizine, desloratadine, … (non-exhausative list) at the moment of biopsy sampling. These should be stopped 2 weeks prior to the biopsy sampling.
  4. Subject is legally incapacitated
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Donation of resection material

    Collection of colonic resection material of subjects undergoing abdominal surgery due to malignancies

    Other: Sample collection

  • Other
    Rectal biopsies

    Collection of rectal biopsies of IBS patients

    Other: Sample collection

Interventions

  • OtherSample collection

    Collection of colonic resection material (surgery patients) and rectal biopsies (IBS patients)

06

What researchers measure

Primary outcomes

  1. Total percentage of degranulated mast cells, detected using fluorescence microscopy

    Using an avidin essay and fluorescence microscopy, the percentage of degranulated mast cells will be quantified

    Time frame: After finishing the essay, approximately on day 2

  2. Total corrected cellular fluorescence (TCCF) per mast cell

    Using an avidin essay and fluorescence microscopy, the TCCF per mast cell will be quantified

    Time frame: After finishing the essay, approximately on day 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartActual
Aug 18, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Apr 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07655375
Lead sponsor
Guy Boeckxstaens
Responsible party
Guy Boeckxstaens (prof. dr., KU Leuven) — Sponsor-investigator
First posted
Jun 17, 2026
Start date
Aug 18, 2026
Primary completion
Oct 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Ine De Booser, MSc
Contact
ine.debooser@uzleuven.be
0032-16-341943
Guy Boecxkstaens, prof. dr.
principal investigator · Catholic University Leuven and Universitary Hospitals Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion